Victrex/£VCT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Victrex
Victrex PLC, founded in 1993 and headquartered in Thornton Cleveleys, UK, is a company that specializes in the manufacturing of high-performance polymeric solutions. It operates in the Specialty Chemicals sector within the materials industry, offering products made primarily from PEEK and PAEK-based materials used in a wide range of sectors including automotive, aerospace, energy, electronics, and medical. Its operations focus on both the development and production of these advanced polymer solutions, catering to both industrial and medical applications across various global markets.
- Ticker
- £VCT
- Sector
- Materials
- Primary listing
- LSE
- Employees
- 1,169
- Headquarters
- Thornton-Cleveleys, United Kingdom
- Website
- www.victrexplc.com
Victrex Metrics
BasicAdvanced
£806M
-
-£0.23
0.75
£0.60
6.40%
Price and volume
Market cap
£806M
Beta
0.75
52-week high
£10.24
52-week low
£5.15
Average daily volume
346K
Dividend rate
£0.60
Financial strength
Current ratio
2.352
Quick ratio
1.02
Long term debt to equity
0.108
Total debt to equity
0.224
Interest coverage (TTM)
17.46%
Profitability
EBITDA (TTM)
64.7
Gross margin (TTM)
43.25%
Net profit margin (TTM)
-6.70%
Operating margin (TTM)
14.26%
Effective tax rate (TTM)
-33.94%
Revenue per employee (TTM)
£250,000
Management effectiveness
Return on assets (TTM)
4.81%
Return on equity (TTM)
-9.44%
Valuation
Price to revenue (TTM)
2.758
Price to book
2.23
Price to tangible book (TTM)
2.34
Price to free cash flow (TTM)
16.611
Free cash flow yield (TTM)
6.02%
Free cash flow per share (TTM)
0.56
Dividend yield (TTM)
6.40%
Growth
Revenue change (TTM)
-1.24%
Earnings per share change (TTM)
-166.54%
3-year revenue growth (CAGR)
-5.03%
10-year revenue growth (CAGR)
1.62%
3-year earnings per share growth (CAGR)
-35.03%
10-year earnings per share growth (CAGR)
-13.25%
10-year dividend per share growth (CAGR)
2.44%
What the Analysts think about Victrex
Analyst ratings (Buy, Hold, Sell) for Victrex stock.
Analyst projections of the future price of Victrex stock.
Bulls say / Bears say
Victrex raised its FY26 underlying profit forecast to £45m–£47m from £42m–£44m after strong fourth-quarter trading across aerospace, value-added resellers and electronics, with growth in every region. This suggests the recovery has broadened beyond a single end market. (Investegate)
Victrex expects global PEEK volumes to grow by about 5% a year over the next five years, supported by existing markets and wider use in new applications. Its established position in PEEK gives it an opportunity to benefit if that adoption continues. (Investegate)
The company’s five-year plan targets about £250m of cumulative levered free cash flow, with at least 75% intended for shareholder returns. It also plans a 30p ordinary dividend for FY26, including a 16.58p final dividend. (Investegate)
Medical revenue fell 9% in the first half, as weaker mix and price pressure, particularly in China, compounded order timing effects. Continued weakness in this division could hold back the recovery. (Investegate)
First-half revenue rose just 1% despite a 6% increase in sales volumes, while underlying pre-tax profit fell 18% to £19m. This shows that higher volumes have not yet translated into stronger earnings, amid adverse mix, pricing and currency effects. (Investegate)
Victrex’s plan relies mainly on internal changes to deliver mid-single-digit revenue growth and much higher margins by FY31, leaving several years of execution ahead. Shares fell more than 10% when the plan was announced, suggesting investors were not convinced by the targets. (Investegate, Digital Look)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
Victrex Financial Performance
Revenues and expenses
Victrex Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Victrex
AllUSDGBPEUR
Fund name | Fund size | £VCT weighting |
|---|---|---|
Global X SuperDividend$SDIV | $978M | 1.50% |
Global X SuperDividend£SDIP | $978M | 1.50% |
iShares FTSE 250£MIDD | £661M | 0.27% |
Vanguard FTSE 250£VMIG | £569M | 0.23% |
Vanguard FTSE 250£VMID | £1.6B | 0.23% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.